Affiliation:
1. Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran
Abstract
Background:
3'-(3,4-dimethoxyphenyl)-4'-(4-(methylsulfonyl)phenyl)-4'H-spiro
[indene-2,5'-isoxazol]-1(3H)-one and 4'-(4-(methylsulfonyl)phenyl)-3'-(3,4,5-trimethoxyphenyl)-
4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one compounds containing indanonic spiroisoxazoline
core are widely known for their antiproliferative activities and investigation of
tubulin binding modes.
Objective:
To evaluate the cytotoxicity effect of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines
against HepG2 cancerous liver cell line and to perform a comparison with
other known anti-liver cancer drugs.
Methods:
The evaluation of cytotoxicity of dimethoxy and trimethoxy indanonic spiroisoxazoline
compounds, Oxaliplatin, Doxorubicin, 5-fluorouracil and Cisplatin against HepG2
(hepatocellular liver carcinoma) cell line has been performed using MTT assay and analyzed
by GraphPad PRISM software (version 8.0.2).
Results:
Potent cytotoxicity effects against HepG2 cell line, comparable to Cisplatin (IC50=
0.047±0.0045 µM), Oxaliplatin (IC50= 0.0051µM), Doxorubicin (IC50= 0.0014µM) and 5-
fluorouracil (IC50= 0.0089 µM), were shown by both dimethoxy (IC50= 0.059±0.012 µM)
and trimethoxy (IC50= 0.086±0.019 µM) indanonic spiroisoxazoline compounds.
Conclusion:
In vitro biological evaluations revealed that dimethoxy and trimethoxy indanonic
spiroisoxazoline compounds are good candidates for the development of new anti-liver
cancer agents.
Publisher
Bentham Science Publishers Ltd.
Reference59 articles.
1. Mukherjee A.K.; Basu S.; Sarkar N.; Ghosh A.C.; Advances in cancer therapy with plant based natural products. Curr Med Chem 2001,8(12),1467-1486
2. Bridges J.F.; Joy S.M.; Gallego G.; Kudo M.; Ye S.L.; Han K.H.; Cheng A.L.; Blauvelt B.M.; Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev 2011,12(10),2585-2591
3. El-Serag H.B.; Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002,35(5)(Suppl. 2),S72-S78
4. Bydder S.; Spry N.A.; Christie D.R.; Roos D.; Burmeister B.H.; Krawitz H.; Davis S.; Joseph D.J.; Poulsen M.; Berry M.; A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australas Radiol 2003,47(3),284-288
5. Rahib L.; Smith B.D.; Aizenberg R.; Rosenzweig A.B.; Fleshman J.M.; Matrisian L.M.; Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014,74(11),2913-2921
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Semisynthesis of new isoxazolines from (E)-α-atlantone: Antibacterial, antifungal activities, ADME-Tox, molecular docking, and molecular dynamics simulations investigations;Journal of Molecular Structure;2024-09
2. Design, Synthesis, Anti-Proliferative and Molecular Docking Studies of Combretastatin A4 Analogues with 2-Azetidinone Moiety;2024
3. Design, Synthesis and Cytotoxicity Evalufation of Substituted Benzimidazole Conjugated 1,3,4-Oxadiazoles;Chemical and Pharmaceutical Bulletin;2022-06-01
4. Synthesis of novel chiral spiro-β-lactams from nitrile oxides and 6-(Z)-(benzoylmethylene)penicillanate: batch, microwave-induced and continuous flow methodologies;RSC Advances;2022
5. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents;Bioorganic & Medicinal Chemistry;2021-02